Galecto Inc (GLTO) USD0.00001

Sell:$2.67Buy:$3.10$0.22 (7.59%)

Prices delayed by at least 15 minutes
Sell:$2.67
Buy:$3.10
Change:$0.22 (7.59%)
Prices delayed by at least 15 minutes
Sell:$2.67
Buy:$3.10
Change:$0.22 (7.59%)
Prices delayed by at least 15 minutes

Company Information

About this company

Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Key people

Hans T. Schambye
President, Chief Executive Officer, Director
Jonathan Freve
Chief Financial Officer
Anders Pedersen
Chief Operating Officer
Garrett Winslow
General Counsel, Corporate Secretary
Stephanie Oestreich
Chief Business Officer
Carl M. Goldfischer
Independent Chairman of the Board
Jayson D.A. Dallas
Independent Director
Chau Q. Khuong
Independent Director
Soren Moller
Independent Director
Amit D. Munshi
Independent Director
Click to see more

Key facts

  • EPIC
    GLTO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US36322Q2066
  • Market cap
    $3.83m
  • Employees
    5
  • Shares in issue
    1.32m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.